EP0646010A4 - Hormone antimullerienne utilisee pour le traitement de tumeurs et la modulation de l'expression de l'antigene d'histocompatibilite majeure classe i. - Google Patents

Hormone antimullerienne utilisee pour le traitement de tumeurs et la modulation de l'expression de l'antigene d'histocompatibilite majeure classe i.

Info

Publication number
EP0646010A4
EP0646010A4 EP93916585A EP93916585A EP0646010A4 EP 0646010 A4 EP0646010 A4 EP 0646010A4 EP 93916585 A EP93916585 A EP 93916585A EP 93916585 A EP93916585 A EP 93916585A EP 0646010 A4 EP0646010 A4 EP 0646010A4
Authority
EP
European Patent Office
Prior art keywords
major histocompatibility
antigen expression
inhibiting substance
treating tumors
histocompatibility antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP93916585A
Other languages
German (de)
English (en)
Other versions
EP0646010A1 (fr
Inventor
Patricia K Donahoe
Tai Wai Chin
Robert L Parry
James Epstein
Richard C Ragin
David T Maclaughlin
Edward M Barksdale
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Publication of EP0646010A1 publication Critical patent/EP0646010A1/fr
Publication of EP0646010A4 publication Critical patent/EP0646010A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP93916585A 1992-06-19 1993-06-18 Hormone antimullerienne utilisee pour le traitement de tumeurs et la modulation de l'expression de l'antigene d'histocompatibilite majeure classe i. Withdrawn EP0646010A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US90163792A 1992-06-19 1992-06-19
US901637 1992-06-19
US712593A 1993-01-21 1993-01-21
US7125 1993-01-21
PCT/US1993/005791 WO1994000133A1 (fr) 1992-06-19 1993-06-18 Hormone antimullerienne utilisee pour le traitement de tumeurs et la modulation de l'expression de l'antigene d'histocompatibilite majeure classe i.

Publications (2)

Publication Number Publication Date
EP0646010A1 EP0646010A1 (fr) 1995-04-05
EP0646010A4 true EP0646010A4 (fr) 1997-04-23

Family

ID=26676562

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93916585A Withdrawn EP0646010A4 (fr) 1992-06-19 1993-06-18 Hormone antimullerienne utilisee pour le traitement de tumeurs et la modulation de l'expression de l'antigene d'histocompatibilite majeure classe i.

Country Status (2)

Country Link
EP (1) EP0646010A4 (fr)
WO (1) WO1994000133A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5558241A (en) * 1994-01-06 1996-09-24 Temp Top Container Systems, Inc. Cryotransport chamber
US6692738B2 (en) 2000-01-27 2004-02-17 The General Hospital Corporation Delivery of therapeutic biologicals from implantable tissue matrices
WO2008116161A2 (fr) 2007-03-22 2008-09-25 The General Hospital Corporation Pyrazoloanthrone et dérivés de celle-ci pour le traitement du cancer et d'états avec excès d'androgène
EP2190481B1 (fr) 2007-07-17 2014-12-24 The General Hospital Corporation Methodes d'identification et d'enrichissement de populations de cellules souches cancereuses ovariennes et de cellules souches somatiques ovariennes et utilisations associees

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5011687A (en) * 1984-06-18 1991-04-30 The General Hospital Corporation Purified Mullerian inhibiting substance and process for treating human ovarian cancer cells
WO1992007943A1 (fr) * 1990-10-31 1992-05-14 Somatix Therapy Corporation Vecteurs de retrovirus efficaces en therapie genique

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU622891B2 (en) * 1985-10-30 1992-04-30 Biogen, Inc. Cleaved dimers of mullerian inhibiting substance-like polypeptides
ATE195876T1 (de) * 1991-04-12 2000-09-15 Gen Hospital Corp Reinigung einer den müller-mischtumor inhibierenden substanz und behandlung von einigen tumoren

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5011687A (en) * 1984-06-18 1991-04-30 The General Hospital Corporation Purified Mullerian inhibiting substance and process for treating human ovarian cancer cells
WO1992007943A1 (fr) * 1990-10-31 1992-05-14 Somatix Therapy Corporation Vecteurs de retrovirus efficaces en therapie genique

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
CATE R.L. ET AL.: "Isolation of the bovine and human genes for Müllerian Inhibiting Substance and expression of the human gene in animal cells.", CELL, vol. 45, June 1986 (1986-06-01), pages 685 - 698, XP002024939 *
KASID A. ET AL: PNAS, 1990, vol. 87, pages 473-477, 'Human gene transfer: Characteriztion of human tumor-infiltrating lymphocytes as vehicles for retroviral-mediated gene transfer in man' *
MACLAUGHLIN D.T.: "Mullerian duct regression and antiproliferative bioactivities of Mullerian Inhibiting Substance reside in its carboxy-terminal domain.", ENDOCRINOLOGY, vol. 131, no. 1, July 1992 (1992-07-01), pages 291 - 296, XP000644378 *
PEPINSKY R.B. ET AL.: "Proteolytic processing of Mullerian Inhibiting Substance produces a transforming growth factor-beta-like fragment.", J.BIOL.CHEM., vol. 263, no. 35, 1988, pages 18961 - 18964, XP002024938 *
RAGIN R.C.: "Human Mullerian Inhibiting Substance: Enhanced purification imparts biochemical stability and restores antiproliferation effect.", PROTEIN EXPRESSION AND PURIFICATION, vol. 3, no. 3, 22 June 1992 (1992-06-22), pages 236 - 245, XP000644388 *
See also references of WO9400133A1 *
SEGEV D.L. ET AL: "Müllerian inhibiting substance inhibits breast cancer cell growth through an NFkB-mediated pathway", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 37, 15 September 2000 (2000-09-15), pages 28371 - 28379, XP002382653, DOI: doi:10.1074/jbc.M004554200 *
SEGEV D.L. ET AL: "Müllerian inhibiting substance regulates NFKB signaling and growth of mammary epithelial cells in vivo", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 29, 20 July 2001 (2001-07-20), pages 26799 - 26806 *
TEIXEIRA J. ET AL: "Müllerian-inhibiting substance regulates androgen synthesis at the transcriptional level", ENDOCRINOLOGY, vol. 140, no. 10, October 1999 (1999-10-01), pages 4732 - 4738 *

Also Published As

Publication number Publication date
WO1994000133A1 (fr) 1994-01-06
EP0646010A1 (fr) 1995-04-05

Similar Documents

Publication Publication Date Title
AU1051495A (en) Device for treating cancer and non-maligant tumors and methods
AP9700939A0 (en) Compounds and methods for the treatment of cancer
ZA977087B (en) Methods of cancer treatment using naaladase inhibitors
FR2695027B1 (fr) Agrafe chirurgicale et appareil pour son impaction.
EP0831880A4 (fr) Anticorps et fragments d'anticorps inhibant la croissance des tumeurs
HUP9902068A3 (en) Methods and compositions for the diagnosis and treatment of cancer
GB9710666D0 (en) Emulsion for well and formation treatment
EP0861539A4 (fr) Fonctions efficaces de hachage cryptographique et procedes de renforcement de la securite des fonctions de hachage et des fonctions pseudo-aleatoires
IL85430A (en) Ultra-violet device and its use for sterilising objects
DZ1741A1 (fr) Méthode et dispositif pour la décomposition pyrolitique d'hydrocarbures.
EP0675723A4 (fr) Therapie utilisant des bisphosphonates et des strogenes en vue de traiter et de prevenir la resorption osseuse.
EP0640097A4 (fr) Compositions et procedes de vaccination contre les coronavirus.
EP0655261A3 (fr) Dispositif pour retarder la chute des cheveux et stimuler leur repousse.
IL96915A0 (en) Method and apparatus for fragmentation of hard substances within the human body
EP0758196A4 (fr) Compositions et procedes de traitement de tumeurs
IL127605A0 (en) Methods of cancer treatment using naaladase inhibitors
ZA933255B (en) Preserved polysiloxane emulsions for treating tissues
ZA954984B (en) Compositions and methods for the treatment of tumors
HK1063004A1 (en) Oxalatoplatin and 5-fluorouracil for combination therapy of cancer
IL127739A0 (en) Retinoyloxy (substituted) alkylene butyrates useful for the treatment of cancer and other proliferative diseases
EP0587777A4 (fr) Proteines de liaison d'antigene carcinoembryonnaire et leurs procedes d'isolation et d'utilisation.
IL115320A0 (en) Retinoyloxy (substituted) methyl butyrates useful for the treatment of cancer and other proliferative diseases
EP0646010A4 (fr) Hormone antimullerienne utilisee pour le traitement de tumeurs et la modulation de l'expression de l'antigene d'histocompatibilite majeure classe i.
AU4953693A (en) Antibody/radioisotope conjugate for tumor diagnosis and/or therapy
AU7770991A (en) Method and composition for the treatment of cancer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950118

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): CH DE DK ES FR GB IE IT LI NL PT SE

RHK1 Main classification (correction)

Ipc: C12N 15/16

A4 Supplementary search report drawn up and despatched

Effective date: 19970306

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): CH DE DK ES FR GB IE IT LI NL PT SE

17Q First examination report despatched

Effective date: 19991221

RTI1 Title (correction)

Free format text: USE OF MULLERIAN INHIBITING SUBSTANCE FOR TREATING TUMORS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 48/00 20060101ALI20060215BHEP

Ipc: C12N 15/86 20060101ALI20060215BHEP

Ipc: C12N 5/10 20060101ALI20060215BHEP

Ipc: C12N 15/16 20060101AFI20060215BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: THE GENERAL HOSPITAL CORPORATION

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060704